Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 10;608(7923):609–617. doi: 10.1038/s41586-022-05066-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Authors 2022, corrected publication 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 8 — a, Representative hematoxylin and eosin (H&E) histochemistry and FGFR2 and E-cadherin immunohistochemistry (IHC) stains on mammary tissue sections from indicated Fgfr2 somatic mouse models. Per MG one tissue section was stained and quantified for each of the indicated stains acquired in multiple independent randomized batches across all Fgfr2 variants. Numbers of stained and quantified MGs are in (b, c). ILC, invasive lobular carcinoma. b, Mammary tumour type classifications of Fgfr2 somatic mouse models based on H&Es and E-cadherin IHC stains. WT, Fgfr2^FL, n = 46 of 20; Fgfr2^ΔE18, n = 45 of 22; Fgfr2^FL-Bicc1, n = 23 of 10; Fgfr2^ΔE18-Bicc1, n = 26 of 11; Fgfr2^ΔE18-Bicc1^ΔSAM, Fgfr2^ΔE18-Ate1, Fgfr2^FL-Tacc2, Fgfr2^E18-C3, n = 20 of 10; Fgfr2^FL-Ate1, Fgfr2^ΔE18-Tacc2, Fgfr2^E18-C4, n = 19 of 10; Fgfr2^ΔE18-IGR1, n = 18 of 9; Fgfr2^ΔE18-IGR2, Fgfr2^E18-C2, n = 17 of 10; Fgfr2^Y674*, Fgfr2^C287R, n = 16 of 8; Fgfr2^T678*, n = 15 of 4; Fgfr2^L681fs*6, n = 14 of 7; Fgfr2^P686*, n = 16 of 5; Fgfr2^S694*, n = 13 of 5; Fgfr2^S697fs*4, n = 8 of 4; Fgfr2^V702*, n = 8 of 3; Fgfr2^Y717*, n = 14 of 5; Fgfr2^N454K, n = 4 injected MGs of 2 mice. Wap-Cre;Cdh1^F/F, Fgfr2^FL, n = 34 of 15; Fgfr2^ΔE18, n = 39 of 15; Fgfr2^FL-Bicc1, n = 17 of 9; Fgfr2^ΔE18-Bicc1, n = 21 of 11; Fgfr2^T678*, n = 13 of 7; Fgfr2^P686*, n = 14 of 4; Fgfr2^S694*, n = 12 of 4; Fgfr2^V702*, n = 12 of 5; Fgfr2^Y717*, n = 11 injected MGs of 4 mice. c, Histo-scoring of FGFR2 IHC stains on mammary tumours from Fgfr2 somatic mouse models. WT, Fgfr2^FL, n = 6 of 5; Fgfr2^ΔE18, n = 39 of 22; Fgfr2^FL-Bicc1, n = 17 of 10; Fgfr2^ΔE18-Bicc1, n = 22 of 11; Fgfr2^ΔE18-Bicc1^ΔSAM, n = 17 of 9; Fgfr2^FL-Ate1, n = 5 of 5; Fgfr2^ΔE18-Ate1, Fgfr2^E18-C4, n = 16 of 9; Fgfr2^FL-Tacc2, n = 12 of 8; Fgfr2^ΔE18-Tacc2, n = 11 of 8; Fgfr2^ΔE18-IGR1, Fgfr2^E18-C3, n = 14 of 9; Fgfr2^ΔE18-IGR2, n = 15 of 10; Fgfr2^E18-C2, n = 12 of 9; Fgfr2^Y674*, n = 14 of 8; Fgfr2^T678*, n = 11 of 4; Fgfr2^L681fs*6, n = 13 of 8; Fgfr2^P686*, Fgfr2^S694*, n = 10 of 5; Fgfr2^S697fs*4, n = 7 of 4; Fgfr2^V702*, n = 6 of 3; Fgfr2^Y717*, n = 10 of 4; Fgfr2^C287R, n = 15 of 8; Fgfr2^N454K, n = 3 tumours of 2 mice. Wap-Cre;Cdh1^F/F, Fgfr2^FL, n = 12 of 8; Fgfr2^ΔE18, n = 23 of 9; Fgfr2^FL-Bicc1, n = 14 of 7; Fgfr2^ΔE18-Bicc1, n = 18 of 10; Fgfr2^T678*, Fgfr2^V702*, n = 10 of 5; Fgfr2^P686*, n = 9 of 4; Fgfr2^S694*, n = 10 of 4; Fgfr2^Y717*, n = 6 tumours of 3 mice. d, Representative H&E histochemistry and E-cadherin and FGFR2 IHC stains on mammary tissue sections from indicated GEMMs. Per MG one tissue section was stained and quantified for each of the indicated stains acquired in two independent randomized batches across all genotypes. Numbers of stained and quantified MGs are in (e, f). e, Mammary tumour type classifications of GEMMs based on H&Es and E-cadherin IHC stains. Wap-Cre;Cdh1^F/+, n = 45 of 12; Wap-Cre;Cdh1^F/+;Fgfr2^FL, n = 20 of 5; Wap-Cre;Cdh1^F/+;Fgfr2^ΔE18, n = 29 of 6; Wap-Cre;Cdh1^F/F, n = 60 of 16; Wap-Cre;Cdh1^F/F;Fgfr2^FL, n = 73 of 19; Wap-Cre;Cdh1^F/F;Fgfr2^ΔE18, n = 79 MGs of 19 mice. f, Histo (H)-score quantifications of FGFR2 IHC stains on mammary tumours from GEMMs. Wap-Cre;Cdh1^F/+, n = 2 of 2; Wap-Cre;Cdh1^F/+;Fgfr2^FL, n = 1 of 1; Wap-Cre;Cdh1^F/+;Fgfr2^ΔE18, n = 8 of 5; Wap-Cre;Cdh1^F/F, n = 9 of 8; Wap-Cre;Cdh1^F/F;Fgfr2^FL, n = 8 of 6; Wap-Cre;Cdh1^F/F;Fgfr2^ΔE18, n = 24 tumours of 19 mice. Data are represented as median (centre line) ± IQR (25^th to 75^th percentile, box) and ± full range (minimum to maximum, whiskers) and P values were calculated with one-tailed Kruskal-Wallis tests and Dunn’s multiple-testing corrections. Scale bars, overview, 500 μm; inset, 50 μm.

Source data